問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Rheumatology

Division of General Internal Medicine

更新時間：2023-09-19

陳英州
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

18Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳英州

List

61Cases

2017-01-01 - 2019-11-30

Phase II

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

  • Condition/Disease

    1. Systemic Lupus Erythematosus and Active Skin Manifestations2. Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

  • Test Drug

    BIIB059

Participate Sites
4Sites

Recruiting4Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2013-04-01 - 2022-12-05

Phase IV

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, AutoantibodyPositive Systemic Lupus Erythematosus Receiving Belimumab

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    BENLYSTA (Belimumab)

Participate Sites
8Sites

Recruiting1Sites

Terminated7Sites

黃春明
China Medical University Hospital

2012-01-01 - 2013-05-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2012-01-01 - 2018-12-31

Phase II

(OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Fostamatinib

Participate Sites
8Sites

Terminated8Sites

2012-04-01 - 2013-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-07-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2011-01-31 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-04-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-11-01 - 2014-11-01

Phase II

A Randomized, Double-Blind, Placebo-Controlled Trial of AC-201 In Subjects with Gout Initiating Urate-Lowering Therapy

  • Condition/Disease

    Gout

  • Test Drug

    AC-201

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

2014-11-03 - 2016-11-01

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF AC 201 IN SUBJECTS WITH GOUT

  • Condition/Disease

    Osteoarthritis

  • Test Drug

    AC-201

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

黃春明
China Medical University Hospital

Division of Rheumatology

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB